OTCMKTS:SLNCF Silence Therapeutics (SLNCF) Stock Price, News & Analysis → You need to know these two things about AI stocks ASAP… (From InvestorPlace) (Ad) Free SLNCF Stock Alerts $7.00 0.00 (0.00%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$7.00▼$7.0050-Day Range$6.50▼$9.0052-Week Range$0.60▼$10.90VolumeN/AAverage Volume1,276 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get Silence Therapeutics alerts: Email Address Ad Manward PressShocking: One AI startup's revenue could surge 4,735%Shocking: One AI Startup's Revenue Could Surge 4,735% While Nvidia gets all the attention, one small AI startup is quietly positioning itself to be the biggest winner.Click here to discover the AI chip company About Silence Therapeutics Stock (OTCMKTS:SLNCF)Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.Read More SLNCF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLNCF Stock News HeadlinesMay 7, 2024 | msn.comSilence Therapeutics files to sell 5.71M American Depositary Shares for holdersMay 5, 2024 | forbes.comFor Mental Health Awareness Month, Let’s Vow To Silence The ShameMay 12, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.May 3, 2024 | msn.comSilence 2 actor Prachi Desai: I don’t take the pressure if I don't have a release in a yearMay 3, 2024 | msn.comHow to complete the Radio Silence quest in Gray Zone WarfareApril 28, 2024 | msn.comPrachi Desai returns in 'Silence 2': higher stakes and a bolder inspector BhatiaApril 28, 2024 | msn.comGet published - enter the Songs of Silence art contestApril 28, 2024 | msn.comIn Sheryl Sandberg's 'Screams Before Silence' Doc, Survivors of Oct. 7 Sexual Violence Speak: 'Mom, They're Going to Rape Me Now'May 12, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 26, 2024 | msn.com'Silence 2' director Aban Bharucha Deohans shares experience working with Manoj Bajpayee, Prachi DesaiApril 26, 2024 | msn.comSilence 2 actor Manoj Bajpayee: Nobody is a superstar on OTT; I'm happy to be relevant and workingApril 26, 2024 | usnews.comBlinken Says Gaza Protests a Hallmark of Democracy, Decries 'Silence' on HamasApril 23, 2024 | msn.comRadio Silence teases bombshell Abigail-Ready or Not connectionApril 16, 2024 | msn.comMovie review: Radio Silence brings maximalist style to vampire flick 'Abigail'April 16, 2024 | msn.comChinese Pop Idol Silence Wang’s Career Under Fire Amidst Sexual Harassment ClaimsApril 9, 2024 | msn.comColorado Springs Cycling Club honors fallen cyclists with “Ride Of Silence” eventApril 9, 2024 | msn.comQuiet on Set: Breaking the Silence Doesn't Let Dan Schneider Have the Last WordApril 4, 2024 | usnews.comDescendants of Enslaved, Enslavers 'Break Silence' Around France's PastApril 3, 2024 | msn.comManoj Bajpayee, Prachi Desai on mission to solve shootout in 'Silence 2'March 31, 2024 | msn.comScream: Radio Silence Discusses Leaving the FranchiseMarch 29, 2024 | msn.comReady or Not 2 gets update with disappointing Radio Silence twistMarch 26, 2024 | msn.comSilence S04 reviewMarch 18, 2024 | news.yahoo.comCalifornia prison guard sentenced in ‘Code of Silence’ cover-up involving inmate deathMarch 18, 2024 | nytimes.comThe Unforgivable Silence on SudanMarch 14, 2024 | markets.businessinsider.comBullish on Silence Therapeutics: Buy Rating Affirmed Amid Strong Phase 2 Results for ZerlasiranMarch 14, 2024 | markets.businessinsider.comThese Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 ResultsMarch 14, 2024 | finance.yahoo.comSilence Therapeutics Full Year 2023 Earnings: Misses ExpectationsSee More Headlines Receive SLNCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:SLNCF CUSIPN/A CIK1479615 Webwww.silence-therapeutics.com Phone442034576900FaxN/AEmployees109Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Craig A. Tooman M.B.A. (Age 59)President, CEO & Executive Director Comp: $1.46MMs. Rhonda L. Hellums (Age 51)CFO & Secretary Comp: $890.6kDr. Steven J. Romano M.D. (Age 65)Head of Research & Development Comp: $650.51kDr. Marie Wikstrom Lindholm Ph.D.Chief Scientific OfficerMs. Gem Gokmen HopkinsHead of IR & Corporate CommunicationsDr. Barbara A. Ruskin J.D. (Age 63)Ph.D., Senior VP and Chief Intellectual Property & Innovation Officer Dr. Eric Floyd M.B.A. (Age 61)M.S., Ph.D., Senior Vice President of Regulatory Affairs & Quality Assurance Mr. J.P. GabrielChief Technical Operations OfficerMr. Curtis Rambaran M.D.Chief Medical OfficerMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors SLNCF Stock Analysis - Frequently Asked Questions How have SLNCF shares performed in 2024? Silence Therapeutics' stock was trading at $1.50 at the start of the year. Since then, SLNCF stock has increased by 366.7% and is now trading at $7.00. View the best growth stocks for 2024 here. How do I buy shares of Silence Therapeutics? Shares of SLNCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:SLNCF) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsYou need to know these two things about AI stocks ASAP…InvestorPlaceGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchMissed NVDA? Buy this AI stock NOWChaikin AnalyticsShocking: One AI startup's revenue could surge 4,735%Manward Press[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silence Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.